Welcome to our dedicated page for Anteris Technologies Global news (Ticker: AVR), a resource for investors and traders seeking the latest updates and insights on Anteris Technologies Global stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anteris Technologies Global's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anteris Technologies Global's position in the market.
Anteris Technologies Global Corp. (AVR) has completed its U.S. initial public offering, raising $88.8 million through the sale of 14.8 million shares at $6.00 per share. The company began trading on NASDAQ on December 13, 2024, under ticker 'AVR'. An additional $13.3 million could be raised if underwriters exercise their Green Shoe option for 2.22 million shares.
The company plans to list its CHESS Depositary Interests on ASX on December 17, 2024. Proceeds will primarily fund the development of DurAVR庐 transcatheter heart valve and a global pivotal study for treating severe aortic stenosis, with remaining funds allocated to working capital and debt repayment.
Anteris Technologies Global Corp. (AVR) has announced the pricing of its U.S. Initial Public Offering of 14,800,000 shares at $6.00 per share. Trading is expected to begin on the Nasdaq Global Market on December 13, 2024, under the ticker symbol 'AVR', with the offering closing on December 16, 2024.
The underwriters have a 30-day option to purchase up to an additional 2,220,000 shares. The company plans to use the proceeds for the development of its DurAVR庐 transcatheter heart valve, preparation for a global pivotal study, working capital, and debt repayment. TD Cowen, Barclays, and Cantor are joint book-running managers, with Lake Street Capital Markets as lead manager.
FAQ
What is the current stock price of Anteris Technologies Global (AVR)?
What is the market cap of Anteris Technologies Global (AVR)?
